ClinicalTrials.gg
CompletedNCT03336710Updated Jul 30, 2019

Perspective on Thoughts and Feelings as a Predictor of Psychological Well-being in Daily Life, in a Community Sample

An observational study in Mental Health and Mindfulness, sponsored by State University of New York at Buffalo. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-30.

Primary conditionPsychological Well-Being(the registry's first term)UnverifiedIs this wrong?Psychological Well-Being is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by State University of New York at Buffalo · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
380
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This project examines the psychological construct of decentering - a mindfulness-related construct marked by an observer perspective on one's ongoing mental processes. Specifically, this project seeks to explore the extent to which decentering modulates the relationship between people's affective states and their momentary mental health and well-being, and to test the psychological processes by which decentering might exert these effects. This study includes a baseline assessment followed by a 7-day study completed from home where participants respond to brief surveys about their current experiences six times per day (i.e., an Ecological Momentary Assessment [EMA] design).

The investigators hypothesize that decentering moderates the association of extreme affect with related symptoms (i.e., elevated negative affect with depression and anxiety; elevated positive affect with mania, narcissism, and histrionic traits) and well-being, such that the association is attenuated at high levels of decentering. This will be examined using the EMA data, analyzing between-person levels (i.e., trait) as well as momentary within-person processes (i.e., concurrent and prospective states).

Further, the investigators predict that broadened attentional focus and improved self-regulation are mechanisms that contribute to the beneficial effects of decentering in daily life. This hypothesis will be examined in two ways:

  1. as individual differences, wherein greater self-regulatory abilities (e.g., higher heart rate variability) and less attentional biases towards emotional stimuli mediate the association between trait decentering and subsequent daily well-being/symptoms, and
  2. as within-person momentary levels, wherein broader attentional processes and greater self-regulation in daily life mediate the concurrent and prospective association between momentary decentering and well-being/symptoms.

Note that the study uses a multimodal assessment of each of the proposed processes. For attentional processes, a variety of parameters extracted from an emotional eye tracking paradigm will be examined. For self-regulatory abilities, assessments will include self-report, physiological (heart rate variability), and behavioral ("go / no-go" task) measures of such abilities.

02

Conditions studied

  • Mental Health
  • Mindfulness

Keywords

  • Self-control
  • Ecological Momentary Assessment
  • Attentional bias
  • Respiratory Sinus Arrhythmia
  • Affect
  • Emotion Regulation
  • Well-being
  • Decentering
  • Affective disorders
03

In context

Psychological Well-Being Unverified

2,193 studies on the registry are indexed under Psychological Well-Being; 728 are open to participants now.

This study's enrollment of 380 is above the median of 300 across 358 observational studies indexed under Psychological Well-Being.

Browse Psychological Well-Being studies →

Lead sponsor

State University of New York at Buffalo is the lead sponsor of 294 studies on the registry; 63 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.

Compared within Psychological Well-Being, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The population from which the sample will be recruited will be residents of the greater Buffalo, NY metropolitan area.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 18-65, fluency in English

Exclusion criteria

Exclusion Criteria:

  • current cognitive impairments (i.e., intellectual disability, dementia, current psychotic symptoms) that preclude giving and accurately answering study questions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
380 participants (actual)
Patient registry
No

Groups and cohorts

  • Primary sample

    Community sample of adults (18-65) from the greater Buffalo, NY region, oversampling people who are seeking mental health treatment.

06

What researchers measure

Primary outcomes

  1. Momentary psychological distress

    2 items (developed new for this study) assessing the presence and impact of idiographic symptoms identified at baseline, and 4 items assessing dysphoria adapted from the Inventory of Depression and Anxiety Symptoms (IDAS)

    Time frame: 6 x daily for 7 days following the baseline assessment

  2. Momentary eudaimonic well-being

    2 items assessing eudaimonic well-being adapted from Breines et al. (2008) and Lambert et al. (2013)

    Time frame: 6 x daily for 7 days following the baseline assessment

  3. Momentary hedonic well-being (state positive and negative affect)

    8 items assessing hedonic well-being (positive and negative affect), taken from the Positive and Negative Affect Schedule (PANAS).

    Time frame: 6 x daily for 7 days following the baseline assessment

  4. State Decentering

    4 items assessing current decentering, adapted from Fresco et al. (2007), Gillanders et al. (2014), and Shoham et al. (2017)

    Time frame: 6 x daily for 7 days following the baseline assessment

  5. Trait Decentering: Experiences Questionnaire

    Experiences Questionnaire is a trait measure of decentering, which assesses the Observer Perspective aspect of decentering. From Fresco et al., (2007)

    Time frame: Baseline session only

  6. Trait decentering: Valence free decentering measure

    This is an in-development measure of decentering that measures the construct of decentering without explicitly referring to negative thoughts and feelings.

    Time frame: Baseline session only

  7. Trait decentering: Cognitive Fusion Questionnaire

    The Cognitive Fusion Questionnaire is a decentering measure that assesses the Reduced Struggle with Inner Experiences aspect of decentering. From Gillanders et al., (2014).

    Time frame: Baseline session only

  8. Trait decentering: Toronto Mindfulness Scale-Decentering Subscale

    The Toronto Mindfulness Scale-Decentering subscale is a decentering measure that assesses the Observer Perspective aspect of decentering. From Davis, Lau, \& Cairns (2009).

    Time frame: Baseline session only

Secondary outcomes

  1. Self-reported momentary self-regulation

    3 questions assessing current perceived willpower \& mental exhaustion, adapted from Davisson (2013) and Milyavskaya \& Inzlicht (2017).

    Time frame: 6 x daily for 7 days following the baseline assessment

  2. Self-reported momentary attentional focus

    4 attentional emotion regulation items (distraction, positive rumination, negative rumination, and reappraisal) adapted from Brans et al. (2013), Feldman et al. (2008), and Nolen-Hoeksema \& Morrow (1991)

    Time frame: 6 x daily for 7 days following the baseline assessment

  3. Baseline self-regulation: Go/no-go task

    Go/no-go task asks people to respond to a large number of "go" trials (80%) and a smaller number of "no go" trials. The ability to inhibit the dominant "go" response is seen as an operative measure of self-regulatory abilities, consequently the number of "no go" signals responded to is one measure of self-regulatory abilities.

    Time frame: Baseline session only

  4. Baseline self-regulation: Resting heart rate variability

    Assessed with a Polar V800 athletic watch during a 5-minute vanilla baseline and a 5-minute paced breathing task.

    Time frame: Baseline session only

  5. Baseline self-regulation: Self-Control Scale (short form)

    A self-report measure of people's perceived self-control abilities and outcomes, developed by Tangney, Baumeister, \& Boone (2004).

    Time frame: Baseline session only

  6. Baseline attentional breadth: Emotional eye-tracking paradigm

    Participants will view a series of emotionally expressive versus neutral faces, and the fixation time and number of fixations towards emotionally evocative (angry, sad, happy) faces will serve as indicators of attentional bias

    Time frame: Baseline session only

  7. Baseline attentional breadth: Thought Control Questionnaire

    Self-report measure corresponding to various emotion regulation strategies (distraction and reappriasal)

    Time frame: Baseline session only

  8. Baseline attentional breadth: Responses to Positive Affect Scale

    Self-report measure corresponding to various emotion regulation strategies (positive rumination)

    Time frame: Baseline session only

  9. Baseline attentional breadth: Ruminative Responses Scale

    Self-report measure corresponding to various emotion regulation strategies (negative rumination)

    Time frame: Baseline session only

07

Study locations

1 site
  • University at Buffalo, Department of psychology
    Buffalo, New York 14260, United States
08

References and documents

Publications

  • Naragon-Gainey K, DeMarree KG. Structure and validity of measures of decentering and defusion. Psychol Assess. 2017 Jul;29(7):935-954. doi: 10.1037/pas0000405. Epub 2016 Oct 31. PubMed 27797554 ↗
  • Bernstein A, Hadash Y, Lichtash Y, Tanay G, Shepherd K, Fresco DM. Decentering and Related Constructs: A Critical Review and Metacognitive Processes Model. Perspect Psychol Sci. 2015 Sep;10(5):599-617. doi: 10.1177/1745691615594577. PubMed 26385999 ↗
  • Shoham A, Goldstein P, Oren R, Spivak D, Bernstein A. Decentering in the process of cultivating mindfulness: An experience-sampling study in time and context. J Consult Clin Psychol. 2017 Feb;85(2):123-134. doi: 10.1037/ccp0000154. PubMed 28134540 ↗
  • Naragon-Gainey K, DeMarree KG. Decentering attentuates the associations of negative affect and positive affect with psychopathology. Clinical Psychological Science. Epub 2017 Aug 11.
  • Tangney JP, Baumeister RF, Boone AL. High self-control predicts good adjustment, less pathology, better grades, and interpersonal success. J Pers. 2004 Apr;72(2):271-324. doi: 10.1111/j.0022-3506.2004.00263.x. PubMed 15016066 ↗
  • Fresco DM, Moore MT, van Dulmen MH, Segal ZV, Ma SH, Teasdale JD, Williams JM. Initial psychometric properties of the experiences questionnaire: validation of a self-report measure of decentering. Behav Ther. 2007 Sep;38(3):234-46. doi: 10.1016/j.beth.2006.08.003. Epub 2007 Apr 24. PubMed 17697849 ↗
  • Gillanders DT, Bolderston H, Bond FW, Dempster M, Flaxman PE, Campbell L, Kerr S, Tansey L, Noel P, Ferenbach C, Masley S, Roach L, Lloyd J, May L, Clarke S, Remington B. The development and initial validation of the cognitive fusion questionnaire. Behav Ther. 2014 Jan;45(1):83-101. doi: 10.1016/j.beth.2013.09.001. Epub 2013 Sep 18. PubMed 24411117 ↗
  • Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70. doi: 10.1037//0022-3514.54.6.1063. PubMed 3397865 ↗
  • Watson D, O'Hara MW, Simms LJ, Kotov R, Chmielewski M, McDade-Montez EA, Gamez W, Stuart S. Development and validation of the Inventory of Depression and Anxiety Symptoms (IDAS). Psychol Assess. 2007 Sep;19(3):253-68. doi: 10.1037/1040-3590.19.3.253. PubMed 17845118 ↗
  • Gross JJ, John OP. Individual differences in two emotion regulation processes: implications for affect, relationships, and well-being. J Pers Soc Psychol. 2003 Aug;85(2):348-62. doi: 10.1037/0022-3514.85.2.348. PubMed 12916575 ↗

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication will be shared.

Supporting information: Study protocol, Informed consent form

Time frame: Materials will be made available 6 months after publication of the primary outcomes.

Access criteria: Data and study materials relevant to any publication will be posted within 6 months of publication on the open science framework, which will be accessible by any interested party.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03336710
Responsible party
Kenneth G. DeMarree (Assistant Professor of Psychology, State University of New York at Buffalo) — Principal investigator
First posted
Nov 8, 2017
Start date
Jul 6, 2017
Primary completion
Dec 7, 2018
Completion
Dec 17, 2018
Last update
Jul 30, 2019

Study contacts

Kristin Gainey, Ph.D.
principal investigator · University at Buffalo
Kenneth G DeMarree, Ph.D.
principal investigator · University at Buffalo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion